Coagulation Disorder clinical trials at UCLA
2 research studies open to eligible people
TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
open to eligible people ages 18 years and up
The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa inhibitors who require urgent surgery/invasive procedure. The participant will be assigned by chance to either TAK-330 or SOC 4F-PCC as part of standard treatment before surgery. Patients participating in this study will need to be hospitalized. They will also be contacted (via telehealth/phone call) 30 days after the surgery.
Torrance, California and other locations
Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
open to eligible people ages 0-20
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Los Angeles, California and other locations
Our lead scientists for Coagulation Disorder research studies include Jaime Deville Brant Putnam, MD.
Last updated: